BACKGROUND: Few investigations have used placenta as an alternative matrix to detect in utero drug exposure, despite its availability at the time of birth and the large amount of sample. Methadone-maintained opioid-dependent pregnant women provide a unique opportunity to examine the placental disposition of methadone and metabolite [2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP)], to explore their correlations with maternal methadone dose and neonatal outcomes, and to test the ability to detect in utero exposure to illicit drugs. METHODS: We calculated the correlations of placental methadone and EDDP concentrations and their correlations with maternal methadone doses and neonatal outcomes. Cocaine- and opiate-positive placenta results were compared with the results for meconium samples and for urine samples collected throughout gestation. RESULTS: Positive correlations were found between placental methadone and EDDP concentrations (r=0.685), and between methadone concentration and methadone dose at delivery (r=0.542), mean daily dose (r=0.554), mean third-trimester dose (r=0.591), and cumulative daily dose (r=0.639). The EDDP/methadone concentration ratio was negatively correlated with cumulative daily dose (r=-0.541) and positively correlated with peak neonatal abstinence syndrome (NAS) score (r=0.513). Placental EDDP concentration was negatively correlated with newborn head circumference (r=-0.579). Cocaine and opiate use was detected in far fewer placenta samples than in thrice-weekly urine and meconium samples, a result suggesting a short detection window for placenta. CONCLUSIONS: Quantitative methadone and EDDP measurement may predict NAS severity. The placenta reflects in utero drug exposure for a shorter time than meconium but may be useful when meconium is unavailable or if documentation of recent exposure is needed.
BACKGROUND: Few investigations have used placenta as an alternative matrix to detect in utero drug exposure, despite its availability at the time of birth and the large amount of sample. Methadone-maintained opioid-dependent pregnant women provide a unique opportunity to examine the placental disposition of methadone and metabolite [2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP)], to explore their correlations with maternal methadone dose and neonatal outcomes, and to test the ability to detect in utero exposure to illicit drugs. METHODS: We calculated the correlations of placental methadone and EDDP concentrations and their correlations with maternal methadone doses and neonatal outcomes. Cocaine- and opiate-positive placenta results were compared with the results for meconium samples and for urine samples collected throughout gestation. RESULTS: Positive correlations were found between placental methadone and EDDP concentrations (r=0.685), and between methadone concentration and methadone dose at delivery (r=0.542), mean daily dose (r=0.554), mean third-trimester dose (r=0.591), and cumulative daily dose (r=0.639). The EDDP/methadone concentration ratio was negatively correlated with cumulative daily dose (r=-0.541) and positively correlated with peak neonatal abstinence syndrome (NAS) score (r=0.513). Placental EDDP concentration was negatively correlated with newborn head circumference (r=-0.579). Cocaine and opiate use was detected in far fewer placenta samples than in thrice-weekly urine and meconium samples, a result suggesting a short detection window for placenta. CONCLUSIONS: Quantitative methadone and EDDP measurement may predict NAS severity. The placenta reflects in utero drug exposure for a shorter time than meconium but may be useful when meconium is unavailable or if documentation of recent exposure is needed.
Authors: Robin E Choo; Constance M Murphy; Hendrée E Jones; Marilyn A Huestis Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2005-01-25 Impact factor: 3.205
Authors: C B Eap; M Bourquin; J Martin; J Spagnoli; S Livoti; K Powell; P Baumann; J Déglon Journal: Drug Alcohol Depend Date: 2000-12-22 Impact factor: 4.492
Authors: Hendree E Jones; Rolley E Johnson; Donald R Jasinski; Kevin E O'Grady; Christian A Chisholm; Robin E Choo; Michael Crocetti; Robert Dudas; Cheryl Harrow; Marilyn A Huestis; Lauren M Jansson; Michael Lantz; Barry M Lester; Lorraine Milio Journal: Drug Alcohol Depend Date: 2005-07 Impact factor: 4.492
Authors: Lauren M Jansson; Robin Choo; Martha L Velez; Cheryl Harrow; Jennifer R Schroeder; Diaa M Shakleya; Marilyn A Huestis Journal: Pediatrics Date: 2008-01 Impact factor: 7.124
Authors: O Quintela; P López; A M Bermejo; M López-Rivadulla Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2006-03-06 Impact factor: 3.205
Authors: Panagiota D Nikolaou; Ioannis I Papoutsis; Julia Atta-Politou; Sotiris A Athanaselis; Chara A Spiliopoulou; Antony C Calokerinos; Constantinos P Maravelias Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2008-04-11 Impact factor: 3.205
Authors: Allison A Vestal-Laborde; Andrew C Eschenroeder; John W Bigbee; Susan E Robinson; Carmen Sato-Bigbee Journal: Dev Neurosci Date: 2014-08-19 Impact factor: 2.984
Authors: Sarah K Himes; Robert S Goodwin; Colleen M Rock; Hendrée E Jones; Rolley E Johnson; Diana G Wilkins; Marilyn A Huestis Journal: Ther Drug Monit Date: 2012-06 Impact factor: 3.681
Authors: Amy L Salisbury; Mara G Coyle; Kevin E O'Grady; Sarah H Heil; Peter R Martin; Susan M Stine; Karol Kaltenbach; Manfred Weninger; Hendrée E Jones Journal: Addiction Date: 2012-11 Impact factor: 6.526